CH BIOTECH SER (08037): BGI Sanghe Investment has completed its acquisition of 6.25% equity in Pengbo (Hainan) held by BGI Sanghe.

CH BIOTECH SER (08037) announced matters related to BGI Songhe Investment. All the preconditions stated in the supplemental agreement have been fulfilled, and BGI Songhe Investment has been completed. As of the date of this announcement, Pengbo (Hainan) is held 6.25% by BGI Songhe. Pengbo (Hainan) will continue to be a non-wholly-owned subsidiary of the company, and the financial statements of Pengbo (Hainan) will continue to be consolidated into the group's financial statements. The completion of the transaction enhances the corporate image and capital base of Pengbo (Hainan). It marks BGI Songhe's confidence in the future development of the boron neutron capture therapy center, as well as the group's commitment to providing boron neutron capture therapy services to cancer patients in need.